Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
MOUNTAIN VIEW, Calif. - Aditxt, Inc. (NASDAQ:ADTX), a micro-cap biotech company with a market capitalization of $5.9 million, has signed a custody agreement with Crypto.com to establish a custodial crypto account, the company announced Monday in a press release. The agreement represents an initial step in the planned rollout of bitXbio, Aditxt’s crypto-native social platform connecting financial technology and biotechnology. According to InvestingPro data, the company’s stock has shown remarkable momentum with a 20.5% gain over the past week.
Under the agreement, Crypto.com Custody will serve as custodian for Aditxt’s proposed digital treasury, supporting the company’s strategy to back biotech innovation with digital assets including Bitcoin. Additionally, Aditxt common stock is now tradable through Crypto.com’s broker-dealer. The company faces financial challenges, with InvestingPro analysis showing a weak financial health score of 1.26 and current ratio of 0.08, indicating potential liquidity concerns.
"We believe that this agreement is a key step in aligning our biotech assets with a next-generation financial infrastructure," said Amro Albanna, Co-founder and CEO of Aditxt.
Eric Anziani, President and Chief Operating Officer of Crypto.com, stated, "Businesses across industries are strategically planning for the future with digital asset treasuries. We are pleased to support Aditxt and its pioneering bitXbio initiative with our best-in-class custodial capabilities."
The initiative is part of Aditxt’s broader bitXbio platform, which aims to expand access to innovations in immune reprogramming, early cancer detection, women’s health, and other health technologies. While the company’s gross profit margins remain challenged, analysts tracked by InvestingPro project revenue growth of 43.8% for fiscal year 2025, suggesting potential improvement in financial performance.
Aditxt is also working toward closing its proposed acquisition of Evofem, with a targeted completion in the second half of 2025. The transaction remains subject to several conditions, including approval by Evofem’s shareholders and Aditxt raising approximately $17 million to meet its closing obligations.
Founded in 2016, Crypto.com serves more than 150 million customers worldwide, while Aditxt operates as a social innovation platform focused on accelerating health innovations. For deeper insights into Aditxt’s financial metrics and 12 additional ProTips, visit InvestingPro.
In other recent news, Aditxt, Inc. has announced that its subsidiary Pearsanta is planning an initial public offering with Spartan Capital Securities as the lead underwriter. This IPO is intended to support the clinical validation and commercial rollout of Pearsanta’s tests, which focus on early detection of cancers and other diseases using their Mitomic mitochondrial DNA platform. Pearsanta has also been invited to submit a full proposal for a U.S. Department of Defense Ovarian Cancer Research Program Pilot Award. The proposal aims to use mitochondrial DNA deletions in plasma as a diagnostic aid for ovarian cancer. Additionally, Aditxt has unveiled a new "bitXbio" strategy that combines Bitcoin reserves with an equity line facility to bolster its biotech commercialization efforts. The company has also welcomed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors, as part of its strategy to expand into the women’s health sector. Furthermore, Aditxt has secured a $233,000 unsecured loan from its CEO, Amro Albanna, which will accrue interest at an annual rate of 7.5%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.